Compare AbCellera Biologics Inc (ABCL) vs Invesco Ltd. (IVZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Invesco Ltd. — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Invesco Ltd. trades at $27.06 (market cap $12.15B). The key difference: Invesco Ltd. is far larger — about 5.2× AbCellera Biologics Inc's market cap, and Invesco Ltd. pays a 3.14% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | IVZ | |
|---|---|---|
Market Cap | $2.35B | $12.15B |
Sector | Health | Financials |
52-Week High | $8.12 | $29.44 |
52-Week Low | $2.78 | $16.69 |
Enterprise Value | $1.99B | $22.39B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Invesco (IVZ) trades at $27.40, up 1.44% today, with a bullish technical signal from moving averages and support at $27. The company reported mixed Q1 2026 earnings, missing estimates, but has beaten expectations in two prior quarters. Revenue grew to $6.38B in 2025, though net income was negative at -$281.70M. Operating cash flow remains strong at $1.53B, and a dividend of $0.22 is scheduled for June 2026.
Outlook: Analyst consensus is mixed with 43% buy ratings and a $29.44 price target, suggesting modest upside. Risks include persistent negative profitability and competitive pressures in asset management. The stock offers value with a P/E of 19.48 but requires monitoring of earnings turnaround and expense management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
